Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

NCT07181499 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Adjuvant Drug Therapy
EGFR

Interventions

DRUG: Befotertinib
DRUG: Pemetrexed + Carboplatin

Sponsor

Betta Pharmaceuticals Co., Ltd.